<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01030939</url>
  </required_header>
  <id_info>
    <org_study_id>112861</org_study_id>
    <nct_id>NCT01030939</nct_id>
  </id_info>
  <brief_title>Study to Investigate Safety, Tolerability, Pharmacokinetics and Cardiac Function After Repeat Doses of SB-649868 in Healthy-volunteers</brief_title>
  <official_title>A Single-blind, Randomised, Placebo-controlled, Parallel Group Study to Investigate Safety, Tolerability, Pharmacokinetics and the Effects on Cardiac Function of Repeat Oral Doses of SB-649868 in Adult and Elderly Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether SB-649868 is safe, tolerable after repeated&#xD;
      administrations in adult and elderly healthy volunteers. Pharmacokinetics and effects on&#xD;
      cardiac function of repeated doses are studied&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present clinical study will assess safety, tolerability and pharmacokinetics of SB-649868&#xD;
      20mg administered for 28 consecutive days in adult (18 to 65 yrs old) and elderly (&gt;65 yrs&#xD;
      old) men and women. The study will also assess cardiac function using echocardiography.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 27, 2009</start_date>
  <completion_date type="Actual">January 6, 2010</completion_date>
  <primary_completion_date type="Actual">January 6, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability evaluated by adverse event monitoring, ECG, vital signs, physical examination, laboratory values (including cTpn I and Insulin) and Romberg/heel to toe test</measure>
    <time_frame>screening period of 28 days followed by 28 days plus a follow up during 2 weeks approximately</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetic after repeat dose. Pharmacodynamic outcomes:Doppler evaluation for tissue velocities, Doppler evaluation of flow, End diastolic and systolic volume and ejection fraction, E/E', and HOMA</measure>
    <time_frame>within 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Sleep Disorders</condition>
  <arm_group>
    <arm_group_label>Cohort 1: SB-649868</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy adult male subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy adult female subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male elderly subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy female elderly subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-649868</intervention_name>
    <description>In each of all cohorts, 18 subjects will be randomised in a 2:1 ratio to receive either SB-649868 or placebo</description>
    <arm_group_label>Cohort 1: SB-649868</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male or female subject as determined by a responsible and experienced&#xD;
             physician, based on a medical evaluation including medical history, physical&#xD;
             examination, laboratory tests and cardiac monitoring. A subject with a clinical&#xD;
             abnormality or laboratory parameters outside the reference range for the population&#xD;
             being studied may be included only if the Investigator and the GSK Medical Monitor&#xD;
             agree that the finding is unlikely to introduce additional risk factors and will not&#xD;
             interfere with the study procedures. However,&#xD;
&#xD;
               -  Subjects with cTpn I values above 99th percentile of normal range of the selected&#xD;
                  assay should always be excluded from enrollment;&#xD;
&#xD;
               -  Subjects with AST or ALT &gt; 2xULN should always be excluded from enrollment;&#xD;
&#xD;
               -  Subjects with alkaline phosphatase or bilirubin &gt; 1.5xULN should always be&#xD;
                  excluded (isolated bilirubin &gt;1.5xULN is acceptable if bilirubin is fractionated&#xD;
                  and direct bilirubin &lt;35%).&#xD;
&#xD;
          2. Age &gt; or equal to 18 years (applied only to Cohort 1 and 2); age &gt;65 years (applied&#xD;
             only to Cohort 3 and 4);&#xD;
&#xD;
          3. Body weight ≥50 kg and BMI within the range 18.5-29.9 kg/m2 inclusive. Slight&#xD;
             deviations from these values will be discussed and approved by the Investigator and&#xD;
             the GSK Medical Monitor to allow subject inclusion into the study&#xD;
&#xD;
          4. Male subjects must agree to use one of the contraception methods listed in Section&#xD;
             8.1. This criterion must be followed from the time of the first dose of study&#xD;
             medication until 3 days post last dose (equivalent to 5 terminal half-lives post-last&#xD;
             dose).&#xD;
&#xD;
          5. A female subject is eligible to participate if she is of:&#xD;
&#xD;
               -  Non-childbearing potential defined as pre-menopausal females with a documented&#xD;
                  tubal ligation or hysterectomy; or postmenopausal defined as 12 months of&#xD;
                  spontaneous amenorrhea [in questionable cases a blood sample with simultaneous&#xD;
                  follicle stimulating hormone (FSH) &gt; 40 MlU/mL and estradiol &lt; 40 pg/ml (&lt;140&#xD;
                  pmol/L) is confirmatory]. Females on hormone replacement therapy (HRT) and whose&#xD;
                  menopausal status is in doubt will be required to use one of the contraception&#xD;
                  methods in Section 8.1 if they wish to continue their Hormone Replacement Therapy&#xD;
                  (HRT) during the study. Otherwise, they must discontinue HRT to allow&#xD;
                  confirmation of post-menopausal status prior to study enrollment. For most forms&#xD;
                  of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the&#xD;
                  blood draw; this interval depends on the type and dosage of HRT. Following&#xD;
                  confirmation of their post-menopausal status, they can resume use of HRT during&#xD;
                  the study without use of contraceptive methods&#xD;
&#xD;
               -  Child-bearing potential and agrees to use one of the contraception methods listed&#xD;
                  in Section 8.1 for an appropriate period of time (as determined by the product&#xD;
                  label or investigator) prior to the start of dosing to sufficiently minimize the&#xD;
                  risk of pregnancy at that point. Female subjects must agree to use contraception&#xD;
                  for 6 weeks following discontinuation of study medication.&#xD;
&#xD;
          6. Having given written informed consent, which includes compliance with the requirements&#xD;
             and restrictions listed in the consent form.&#xD;
&#xD;
          7. Average QTcB or QTcF &lt; 450 msec; PQ 120-220ms; QRS &lt;120ms; no significant rhythm&#xD;
             disorders in SCR 24h Holter-ECG&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or presence of significant psychiatric, neurological, respiratory,&#xD;
             gastrointestinal, hepatic, pancreatic or renal diseases or of any condition known to&#xD;
             interfere with the absorption, distribution, metabolism or excretion of drugs.&#xD;
&#xD;
          2. History of cardiovascular diseases and/or evidence of repolarization defects&#xD;
&#xD;
          3. History of regular alcohol consumption within 6 months of the study defined as:&#xD;
&#xD;
             • an average weekly intake of greater than 21 units (14 units for female) or an&#xD;
             average daily intake of greater than 3 units (2 units for female). 1 unit is&#xD;
             equivalent to a half-pint (220mL) of beer or 1 (25ml) measure of spirits or 1 glass&#xD;
             (125ml) of wine.&#xD;
&#xD;
          4. History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the investigator or GSK&#xD;
             Medical Monitor, contraindicates their participation.&#xD;
&#xD;
          5. Vulnerable subjects , or subject is mentally or legally incapacitated, or language&#xD;
             barrier precluding adequate understanding of cooperation.&#xD;
&#xD;
          6. Any history of suicidal behaviour or any suicidal ideation of type 4 or 5 in the last&#xD;
             month on the C-SSRS administered at screening&#xD;
&#xD;
          7. Pregnant females as determined by positive Serum beta-hCG test at screening or prior&#xD;
             to dosing.&#xD;
&#xD;
          8. Lactating females.&#xD;
&#xD;
          9. A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody&#xD;
             result within 3 months of screening&#xD;
&#xD;
         10. A positive test for HIV antibody.&#xD;
&#xD;
         11. cTpn I values above of 99th percentile of the laboratory reference interval&#xD;
&#xD;
         12. A positive pre-study drug/alcohol screen.&#xD;
&#xD;
         13. Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or&#xD;
             nicotine-containing products within 6 months prior to screening.&#xD;
&#xD;
         14. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary&#xD;
             supplements (including St John's Wort) within 7 days (or 14 days if the drug is a&#xD;
             potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first&#xD;
             dose of study medication, unless in the opinion of the Investigator and GSK Medical&#xD;
             Monitor the medication will not interfere with the study procedures or compromise&#xD;
             subject safety.&#xD;
&#xD;
         15. Consumption of broccoli, radish sprouts, cauliflower, cabbage, orange juice,&#xD;
             grapefruit juice or grapefruit within 7 days prior to the first dose of study&#xD;
             medication until collection of the final pharmacokinetic blood sample.&#xD;
&#xD;
         16. The subject has participated in a clinical trial and has received an IP within the&#xD;
             following time period prior to the first dosing day in the current study: 30 days, 5&#xD;
             half-lives or twice the duration of the biological effect of the IP (whichever is&#xD;
             longer).&#xD;
&#xD;
         17. Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
         18. Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500 mL within a 56 day period.&#xD;
&#xD;
         19. Unwillingness or inability to follow the procedures outlined in the protocol.&#xD;
&#xD;
         20. The subject is unable or unwilling to abstain from strenuous physical activity in the&#xD;
             48 h before screening and up to the follow up visit.&#xD;
&#xD;
         21. Subject is the investigator or his/her deputies, research assistant, pharmacist, study&#xD;
             coordinator, other staff or relative thereof involved in the conduct of the study.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>November 12, 2009</study_first_submitted>
  <study_first_submitted_qc>December 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2009</study_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <keyword>Men and women</keyword>
  <keyword>adults and elderly</keyword>
  <keyword>repeat dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Wake Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>112861</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112861</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112861</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112861</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112861</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112861</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112861</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

